Contrasting Role of COMMD5 in Renal Cell Carcinoma: Tumor Suppression and Metastatic Enhancement.

IF 1.6 4区医学 Q4 ONCOLOGY

Anticancer research Pub Date : 2025-04-01 DOI:10.21873/anticanres.17523

Hiroyuki Matsuda, Jin Ikeda, Maiko Ogasawara-Nosoko, Morito Endo, Pavel Hamet, Johanne Tremblay

{"title":"Contrasting Role of COMMD5 in Renal Cell Carcinoma: Tumor Suppression and Metastatic Enhancement.","authors":"Hiroyuki Matsuda, Jin Ikeda, Maiko Ogasawara-Nosoko, Morito Endo, Pavel Hamet, Johanne Tremblay","doi":"10.21873/anticanres.17523","DOIUrl":null,"url":null,"abstract":"Background/aim: Despite diagnostic and therapeutic advances, renal cell carcinoma (RCC) metastasis remains difficult to eliminate. Copper metabolism MURR1 domain-containing 5 (COMMD5), a protein involved in tubular epithelial integrity, is implicated in RCC tumorigenesis. This study explored its role in RCC metastasis.Materials and methods: Proliferation, adhesion, and survival under hypoxia in RCC cells over-expressing COMMD5 were evaluated. A murine model was used to evaluate metastatic potential in vivo. Clinical data were analyzed for correlations between COMMD5 expression and patient outcomes.Results: COMMD5 over-expression facilitated cancer cell differentiation and suppressed proliferation but enhanced adhesion and survival under hypoxia. In vivo, it reduced metastatic lung nodule growth but increased the number of metastatic lung nodules. Clinically, high COMMD5 expression in normal kidneys correlated with smaller RCC size, while high COMMD5 expression in tumors was linked to poor metastasis-free survival.Conclusion: COMMD5 plays dual roles in RCC progression, as a tumor suppressor and a metastasis enhancer.","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 4","pages":"1373-1385"},"PeriodicalIF":1.6000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anticancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/anticanres.17523","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background/aim: Despite diagnostic and therapeutic advances, renal cell carcinoma (RCC) metastasis remains difficult to eliminate. Copper metabolism MURR1 domain-containing 5 (COMMD5), a protein involved in tubular epithelial integrity, is implicated in RCC tumorigenesis. This study explored its role in RCC metastasis.

Materials and methods: Proliferation, adhesion, and survival under hypoxia in RCC cells over-expressing COMMD5 were evaluated. A murine model was used to evaluate metastatic potential in vivo. Clinical data were analyzed for correlations between COMMD5 expression and patient outcomes.

Results: COMMD5 over-expression facilitated cancer cell differentiation and suppressed proliferation but enhanced adhesion and survival under hypoxia. In vivo, it reduced metastatic lung nodule growth but increased the number of metastatic lung nodules. Clinically, high COMMD5 expression in normal kidneys correlated with smaller RCC size, while high COMMD5 expression in tumors was linked to poor metastasis-free survival.

Conclusion: COMMD5 plays dual roles in RCC progression, as a tumor suppressor and a metastasis enhancer.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Anticancer research 医学-肿瘤学

CiteScore

3.70

自引率

10.00%

发文量

566

审稿时长

2 months

期刊介绍： ANTICANCER RESEARCH is an independent international peer-reviewed journal devoted to the rapid publication of high quality original articles and reviews on all aspects of experimental and clinical oncology. Prompt evaluation of all submitted articles in confidence and rapid publication within 1-2 months of acceptance are guaranteed. ANTICANCER RESEARCH was established in 1981 and is published monthly (bimonthly until the end of 2008). Each annual volume contains twelve issues and index. Each issue may be divided into three parts (A: Reviews, B: Experimental studies, and C: Clinical and Epidemiological studies). Special issues, presenting the proceedings of meetings or groups of papers on topics of significant progress, will also be included in each volume. There is no limitation to the number of pages per issue.